company,total_score,fit_score,urgency_score,access_score,trial_count,best_fit_trial_title,best_fit_trial_status,best_fit_trial_phases,best_fit_trial_last_update,recent_job_hits,fit_reason,urgency_reason,urgency_source,access_reason,bonus_recent_trial,bonus_multi_trial,trigger_summary,evidence_links,target_roles,job_hit_keywords,job_hit_titles
AstraZeneca,9.10,3.0,3.0,2.0,7,"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-10,0,trial title indicates T-cell engager / T-cell engaging / T-cell redirecting,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,company on watchlist / ATS known,0.5,0.6,"trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. | trial_candidate: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | trial_candidate: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",https://clinicaltrials.gov/study/NCT06542250 ; https://clinicaltrials.gov/study/NCT06564038 ; https://clinicaltrials.gov/study/NCT05877599 ; https://clinicaltrials.gov/study/NCT06218914 ; https://clinicaltrials.gov/study/NCT06005493 ; https://clinicaltrials.gov/study/NCT07215585 ; https://clinicaltrials.gov/study/NCT07201558,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
Pfizer,8.10,2.0,3.0,2.0,6,MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide),RECRUITING,"[""PHASE3""]",2026-02-03,0,trial title contains CD3,trial status RECRUITING and phase in ['PHASE1'],trial,company on watchlist / ATS known,0.5,0.6,trial_candidate: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | trial_candidate: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | trial_candidate: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments,https://clinicaltrials.gov/study/NCT06215118 ; https://clinicaltrials.gov/study/NCT06152575 ; https://clinicaltrials.gov/study/NCT05020236 ; https://clinicaltrials.gov/study/NCT06057402 ; https://clinicaltrials.gov/study/NCT05090566 ; https://clinicaltrials.gov/study/NCT04649359,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
GSK,3.00,1.0,0.0,2.0,0,,,,,0,no trials,no trials and no relevant jobs,none,company on watchlist / ATS known,0.0,0.0,,,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
